News and thoughts:

Cell Stress, Vol. 1, No. 1, pp. 4 - 6; doi: 10.15698/cst2017.10.102

The long non-coding RNA H19 – a new player in hepatocellular carcinoma

Maximilian A. Ardelt1 and Johanna Pachmayr2

Download PDF download pdf
Show/hide additional information

    1 Department of Pharmacy, Pharmaceutical Biology, University of Munich, Munich, Germany.

    2 Pharmacy, Pharmaceutical Biology&Clinical Pharmacy, Paracelsus Medical University, Salzburg, Austria.

Keywords: lncRNA, H19, HCC.
Received originally: 08/09/2017 Accepted: 14/09/2017 Published: 01/10/2017

Johanna Pachmayr, Pharmacy, Pharmaceutical Biology&Clinical Pharmacy, Paracelsus Medical University, Salzburg, Austria

Conflict of interest statement: None.
Please cite this article as: Maximilian A. Ardelt and Johanna Pachmayr (2017). The long non-coding RNA H19 – a new player in hepatocellular carcinoma. Cell Stress 1(1): 4-6. doi: 10.15698/cst2017.10.102

Hepatocellular carcinoma (HCC) is among the most prevalent and lethal cancers worldwide [1]. Incidence is increasing and due to its high chemoresistance, the therapeutic options are limited and HCC has risen to become one of the leading causes of cancer-related death [2]. Thus, a detailed characterization of the mechanisms of HCC chemoresistance is urgently required in order to find new therapeutic approaches to overcome HCC chemoresistance.

The study by Schultheiss et al. suggests an interesting player to overcome chemoresistance in HCC: the long non-coding RNA (lncRNA) H19 [3]. LncRNAs have recently emerged as pivotal players in cancer, due to their contribution to cancer development, metastasis and chemoresistance [4]. H19 was associated with various types of cancer, but its role in cancer is conflicting, as tumor-promoting and tumor-suppressive actions have been demonstrated [5][6][7]. H19 was shown to be regulated under inflammatory conditions [5] and has been linked with HCC that represents a type of tumor that is associated with inflammatory conditions such as found in viral hepatitis as well as in alcoholic and non-alcoholic steatohepatitis [8][9][10]. However, the reports about H19 in HCC are contradictory and H19 was described both to promote as well as to suppress tumor development [9][10][11]. Thus, the role of H19 in HCC is still unclear.

In order to investigate the expression of H19 in HCC, Schultheiss et al. used four independent patient cohorts which revealed a decreased expression of H19 in human HCC tissue compared to non-tumorous tissue. However, interestingly, although H19 was downregulated in HCC, in each of the investigated patient cohorts a high H19 expression was observed in a small patient subgroup. This might explain the contradictory findings about H19 expression in small patient cohorts. In line with H19 levels, the expression of miR 675, which is encoded by H19 [12][13], was decreased, whereas the expression of the mRNA binding protein EVAL1, a negative regulator of miR-675, was increased in HCC tissues.

Subsequently, the authors addressed the mechanisms underlying the decreased expression of H19 in HCC. H19 expression can be regulated by loss of imprinting (LOI) and by differential promoter methylation [14]. Schultheiss et al. showed that the decreased H19 expression was not due to LOI. Interestingly, H19 promoter methylation was decreased in HCC compared to normal liver tissue, suggesting that decreased expression of H19 correlates with decreased promotor methylation. However, elevated gene expression is normally based on decreased promoter methylation. Nevertheless, an association of hypermethylation and increased gene expression has been described as well [15]. Thus, the relationship between H19 promotor methylation and expression in HCC needs further investigation and will be an interesting topic for further research.

To further determine the function and regulation of H19 in HCC, the authors used three different HCC cell lines, including HepG2, Plc/Prf/5, and Huh7. H19 overexpression impaired clonogenic growth and improved the response of HCC cells to the treatment with sorafenib and doxorubicin, suggesting a chemosensitizing effect of H19. However, determination of the influence of H19 overexpression and knockdown on cell viability and proliferation revealed cell line specific differences: except for an elevation of viability of HepG2 cells, HCC cell viability was not affected by H19 overexpression or knockdown. Moreover, whereas proliferation of HepG2 cells was not affected, H19 overexpression reduced proliferation of Plc/Prf/5 and Huh7 cells. These data suggest a rather context-dependent function of H19 in HCC. Investigating H19 signaling suggested that neither miR-675 nor ELAV1 or IGF2 contributed to the sensitizing effect of H19, as these components were not modulated in cells with H19 upregulation. Thus, the signaling network of H19 in HCC remains an interesting question for future research.

In order to evaluate whether H19 contributes to chemoresistance, Schultheiss et al. generated doxorubicin- and sorafenib-resistant HepG2, Plc/Prf/5 and Huh7 cells. In fact, downregulation of H19 in the resistant cell lines suggested an association of H19 suppression with chemoresistance. Moreover, H19 promotor methylation was changed during chemoresistance, but again cell-line specific differences were observed: all three sorafenib-resistant cell lines as well as doxorubicin-resistant HUH7 cells showed elevated promoter methylation with differences in the specific CpG sites, whereas doxorubicin-resistant HepG2 and Plc/Prf/5 cells showed a heterogenous hyper- or hypomethylation of the different CpG sites. As most of the changes were observed nearest to the transcription start site, the authors suggested that the modified promotor methylation contributes to decreased H19 expression during chemoresistance. Therefore, Schultheiss et al. investigated the influence of the DNA-demethylating agent 5-azacytidine on HCC cell chemoresistance. 5-azacytidine decreased H19 promoter methylation and increased H19 expression in HepG2 and Huh7 cells but not in Plc/Prf/5 cells. Moreover, 5-azacytidine sensitized HCC cells to doxorubicin treatment. As H19 overexpression improved cell death induction by doxorubicin and inhibited proliferation of chemoresistant HCC cells, H19 overexpression was suggested as potential approach to overcome chemoresistance in HCC.

Finally, the influence of H19 on tumor induction was investigated. In fact, H19 deficient mice demonstrated increased tumor development by the carcinogen diethylnitrosamine (DEN) with tumors that showed increased cell proliferation as well as dysplastic lesions characteristic for liver carcinogenesis.

In summary, the study by Schultheiss et al. shows that the lncRNA H19 is downregulated in HCC tissues and that it suppresses chemoresistance and tumorigenesis. The contribution of H19 promotor methylation and the cell-line specific effects of H19 open exciting questions for future research. To conclude, the study by Schultheiss et al. helps to understand the function of H19 in HCC and suggests H19 as a potential target to overcome chemoresistance in HCC.


  1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman, "Global cancer statistics", CA: A Cancer Journal for Clinicians, vol. 61, pp. 69-90, 2011.
  2. J. Bruix, and M. Sherman, "Management of hepatocellular carcinoma: An update", Hepatology, vol. 53, pp. 1020-1022, 2011.
  3. C. Schultheiss, S. Laggai, B. Czepukojc, U. Hussein, M. List, A. Barghash, S. Tierling, K. Hosseini, N. Golob-Schwarzl, J. Pokorny, N. Hachenthal, M. Schulz, V. Helms, J. Walter, V. Zimmer, F. Lammer, R. Bohle, L. Dandolo, J. Haybaeck, A. Kiemer, and S. Kessler, "The long non-coding RNA H19 suppresses carcinogenesis and chemoresistcance in hepatocellular carcinoma.", Cell Stress 1(1): 37-54., 2017.
  4. M. Esteller, "Non-coding RNAs in human disease", Nature Reviews Genetics, vol. 12, pp. 861-874, 2011.
  5. W. Wang, H. Ye, P. Wei, B. Han, B. He, Z.H. Chen, and Y. Chen, "LncRNAs H19 and HULC, activated by oxidative stress, promote cell migration and invasion in cholangiocarcinoma through a ceRNA manner", Journal of Hematology & Oncology, vol. 9, 2016.
  6. M. Ohtsuka, H. Ling, C. Ivan, M. Pichler, D. Matsushita, M. Goblirsch, V. Stiegelbauer, K. Shigeyasu, X. Zhang, M. Chen, F. Vidhu, G.A. Bartholomeusz, Y. Toiyama, M. Kusunoki, Y. Doki, M. Mori, S. Song, J.R. Gunther, S. Krishnan, O. Slaby, A. Goel, J.A. Ajani, M. Radovich, and G.A. Calin, "H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-β-Catenin Signaling in Colorectal Cancer", EBioMedicine, vol. 13, pp. 113-124, 2016.
  7. S. Wang, X. Wu, M. Zhang, M. Weng, D. Zhou, and Z. Quan, "Long noncoding RNA H19 contributes to gallbladder cancer cell proliferation by modulated miR-194-5p targeting AKT2", Tumor Biology, vol. 37, pp. 9721-9730, 2016.
  8. H.B. El–Serag, and K.L. Rudolph, "Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis", Gastroenterology, vol. 132, pp. 2557-2576, 2007.
  9. T. Yoshimizu, A. Miroglio, M. Ripoche, A. Gabory, M. Vernucci, A. Riccio, S. Colnot, C. Godard, B. Terris, H. Jammes, and L. Dandolo, "The H19 locus acts in vivo as a tumor suppressor", Proceedings of the National Academy of Sciences, vol. 105, pp. 12417-12422, 2008.
  10. I.J. Matouk, N. DeGroot, S. Mezan, S. Ayesh, R. Abu-lail, A. Hochberg, and E. Galun, "The H19 Non-Coding RNA Is Essential for Human Tumor Growth", PLoS ONE, vol. 2, pp. e845, 2007.
  11. Y. He, X. Meng, C. Huang, B. Wu, L. Zhang, X. Lv, and J. Li, "Long noncoding RNAs: Novel insights into hepatocelluar carcinoma", Cancer Letters, vol. 344, pp. 20-27, 2014.
  12. X. Cai, and B.R. Cullen, "The imprinted H19 noncoding RNA is a primary microRNA precursor", RNA, vol. 13, pp. 313-316, 2007.
  13. A. Keniry, D. Oxley, P. Monnier, M. Kyba, L. Dandolo, G. Smits, and W. Reik, "The H19 lincRNA is a developmental reservoir of miR-675 that suppresses growth and Igf1r", Nature Cell Biology, vol. 14, pp. 659-665, 2012.
  14. A. Gabory, M. Ripoche, T. Yoshimizu, and L. Dandolo, "The <i>H19</i> gene: regulation and function of a non-coding RNA", Cytogenetic and Genome Research, vol. 113, pp. 188-193, 2006.
  15. J. Wu, Y. Qin, B. Li, W. He, and Z. Sun, "Hypomethylated and hypermethylated profiles of H19DMR are associated with the aberrant imprinting of IGF2 and H19 in human hepatocellular carcinoma", Genomics, vol. 91, pp. 443-450, 2008.


© 2017

Creative Commons License
The long non-coding RNA H19 – a new player in hepatocellular carcinoma by Ardelt and Pachmayr is licensed under a Creative Commons Attribution 4.0 International License.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this. Please refer to our "privacy statement" and our "terms of use" for further information.